Role of SAP (SH2D1A) gene in T cell-dependent antibody response

SAP (SH2D1A) 基因在 T 细胞依赖性抗体反应中的作用

基本信息

项目摘要

X-linked lymphoproliferative syndrome (XLP) is characterized by three prevalent phenotypes: 1) Fulminant Infectious Mononucleosis, 2) malignant B cell lymphoma and 3) acquired hypogammaglobulinema in the absence of infectious mononucleosis. As the three major phenotypes of XLP are found within one family harboring the same mutation, genetic background and/or environmental factors must play a role in the pathogenesis of the disease. FIM patients mount a vigorous, uncontrolled polyclonal expansion of T and B cells, inevitably leading to death by hepatic necrosis and bone marrow failure. A major cause of XLP in humans is a defect in the SH2D1A gene, which encodes SAP (SLAM Associated Protein), a single free SH2- domain protein that controls distinct key signal transduction pathways in CD4 and CDS T lymphocytes, NK cells, platelets and probably a subset of B cells. SAP functions as an adapter, which bridges the cytoplasmic tail of six members of the SLAM receptor family to signal transduction pathways, e.g. Fyn and other tyrosine kinases. Previous studies show that several arms of the acquired immune responses are affected in XLP patients and SAP-deficient mice and that the SAP related molecules EAT-2A and -2B subserve similar functions. Our general hypothesis is that SAP and EAT-2A/B control partially overlapping mechanisms that are critical for the control of humoral immunity. The experiments proposed in this application will test the hypothesis that #1) distinct SAP-/- CD4+ T cell subsets and/or NKT cells contribute to the dysgammaglobulinemia of SAP-/- mice, #2) disruption of the SAP gene affects the subsets of follicular B cells, which participate in humoral responses and in the germinal center reaction and #3) EAT-2A/B and SAP interact in the control of antibody responses. Together these experiments should clarify the role of SAP and EAT-2 in T cell dependent B cell responses and why the absence of SAP functions causes dys-gammaglobulinemia. The results of these studies should suggest therapeutic strategies that can be applied to XLP patients.
X连锁淋巴组织增生综合征(XLP)主要表现为三种表型:1)暴发型 传染性单核细胞增多症,2)恶性B细胞淋巴瘤和3)获得性低丙种球蛋白血症 无传染性单核细胞增多症。由于XLP的三种主要表型在一个家族中发现, 携带相同的突变,遗传背景和/或环境因素必须发挥作用, 疾病的发病机制。THP患者T和B的多克隆扩增剧烈,不受控制 细胞,不可避免地导致肝坏死和骨髓衰竭而死亡。XLP的一个主要原因是 人类是SH2D1A基因的缺陷,该基因编码SAP(SLAM相关蛋白),一个单一的游离SH2- 一种控制CD4和CD8 T淋巴细胞中不同关键信号转导途径的结构域蛋白,NK 细胞、血小板和可能的B细胞亚群。SAP作为一个衔接子, SLAM受体家族的六个成员的尾部与信号转导途径,例如Fyn和其他酪氨酸 激酶。 先前的研究表明,XLP患者的获得性免疫反应的几个分支受到影响 SAP相关分子EAT-2A和EAT-2B具有相似的功能。我们 一般假设是SAP和EAT-2A/B控制部分重叠的机制,这些机制对于 控制体液免疫。本申请中提出的实验将检验以下假设: #1)不同的SAP-/-CD4 + T细胞亚群和/或NKT细胞促成SAP-/-CD4 + T细胞亚群的异常丙种球蛋白血症。 小鼠,#2)SAP基因的破坏影响滤泡B细胞的亚群,其参与体液免疫调节。 EAT-2A/B和SAP在抗体控制中相互作用 应答 总之,这些实验应该阐明SAP和EAT-2在T细胞依赖性B细胞应答中的作用 以及为什么SAP功能缺失会导致异常丙种球蛋白血症。这些研究的结果应该 提出了可应用于XLP患者的治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CORNELIS P TERHORST其他文献

CORNELIS P TERHORST的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CORNELIS P TERHORST', 18)}}的其他基金

Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
  • 批准号:
    8296689
  • 财政年份:
    2009
  • 资助金额:
    $ 30.1万
  • 项目类别:
Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
  • 批准号:
    7560933
  • 财政年份:
    2009
  • 资助金额:
    $ 30.1万
  • 项目类别:
Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
  • 批准号:
    8102821
  • 财政年份:
    2009
  • 资助金额:
    $ 30.1万
  • 项目类别:
Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
  • 批准号:
    7882569
  • 财政年份:
    2009
  • 资助金额:
    $ 30.1万
  • 项目类别:
Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
  • 批准号:
    8501241
  • 财政年份:
    2009
  • 资助金额:
    $ 30.1万
  • 项目类别:
IMMUNE
免疫
  • 批准号:
    7885362
  • 财政年份:
    2009
  • 资助金额:
    $ 30.1万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7614102
  • 财政年份:
    2009
  • 资助金额:
    $ 30.1万
  • 项目类别:
SLAM Gene Family Controlled Pathways to SLE
SLAM 基因家族控制 SLE 通路
  • 批准号:
    7275918
  • 财政年份:
    2006
  • 资助金额:
    $ 30.1万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8733827
  • 财政年份:
    2006
  • 资助金额:
    $ 30.1万
  • 项目类别:
The Slamf3, Slamf5, and Slamf6 receptor-induced pathways to murine lupus
Slamf3、Slamf5 和 Slamf6 受体诱导的小鼠狼疮途径
  • 批准号:
    8345511
  • 财政年份:
    2006
  • 资助金额:
    $ 30.1万
  • 项目类别:

相似海外基金

Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
  • 批准号:
    10549640
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
  • 批准号:
    2750554
  • 财政年份:
    2021
  • 资助金额:
    $ 30.1万
  • 项目类别:
    Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
  • 批准号:
    61319
  • 财政年份:
    2020
  • 资助金额:
    $ 30.1万
  • 项目类别:
    Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10013588
  • 财政年份:
    2020
  • 资助金额:
    $ 30.1万
  • 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
  • 批准号:
    20K07009
  • 财政年份:
    2020
  • 资助金额:
    $ 30.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
  • 批准号:
    10603473
  • 财政年份:
    2020
  • 资助金额:
    $ 30.1万
  • 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
  • 批准号:
    2342674
  • 财政年份:
    2020
  • 资助金额:
    $ 30.1万
  • 项目类别:
    Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
  • 批准号:
    10117194
  • 财政年份:
    2020
  • 资助金额:
    $ 30.1万
  • 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10115604
  • 财政年份:
    2020
  • 资助金额:
    $ 30.1万
  • 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
  • 批准号:
    10294224
  • 财政年份:
    2018
  • 资助金额:
    $ 30.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了